Stromal cell-derived factor-1 alpha alleviates hypoxic-ischemic brain damage in mice

Area of Science:

• Neuroscience
• Regenerative Medicine
• Molecular Biology

Background:

• Hypoxic-ischemic brain damage (HIBD) is a significant cause of mortality and long-term neurological deficits.
• Stromal cell-derived factor-1 alpha (SDF-1α) shows therapeutic potential in ischemic conditions.

Purpose of the Study:

• To investigate the therapeutic effects of intraperitoneal SDF-1α administration following experimental hypoxia-ischemia (HI).
• To elucidate the underlying mechanisms, including apoptosis and stem cell mobilization, involved in SDF-1α treatment for HIBD.

Main Methods:

• 129 mice underwent unilateral carotid artery ligation and 2.5 hours of hypoxia.
• Mice were randomized into sham, HI + vehicle, and HI + SDF-1α treatment groups.
• Evaluated spatial learning, neuropathology, apoptosis, SDF-1α/CXC chemokine receptor-4 (CXCR4) expression, and mesenchymal stem cell (MSC) counts.

Main Results:

• SDF-1α treatment improved spatial learning and neuropathological outcomes in HI mice.
• Apoptotic cell numbers decreased, while SDF-1α and CXCR4 expression increased post-SDF-1α treatment.
• Mesenchymal stem cell (MSC) counts were elevated in peripheral blood after SDF-1α administration.

Conclusions:

• Intraperitoneal SDF-1α administration promotes functional recovery after HIBD.
• The therapeutic benefits are associated with reduced apoptosis and SDF-1α/CXCR4-mediated MSC mobilization.